Phenoxybenzamine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Phenoxybenzamine: From Phaeochromocytoma to Primary Hereditary Glaucoma
One-Sentence Summary
Phenoxybenzamine is a long-established, non-selective α1/α2-adrenergic antagonist, historically used for phaeochromocytoma and related catecholamine-excess states (general pharmacological knowledge — this drug is not currently marketed in Australia, so no local regulatory indication text is available). The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, but this direction is currently supported by no clinical trials and no literature, and the proposed mechanism runs counter to established glaucoma pharmacology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Australian regulatory data (drug not marketed in Australia); historically used for phaeochromocytoma / hypertensive crises (general pharmacological reference, not sourced from this evidence pack) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for this drug is not available in the structured dataset (original_moa is a data gap). Drawing on the repurposing rationale supplied alongside this prediction: Phenoxybenzamine is an irreversible, non-selective α1/α2-adrenergic receptor antagonist.
Intraocular pressure control in glaucoma is typically achieved through α2-agonists (e.g. brimonidine), which reduce aqueous humour production, or through β-blockers and prostaglandin analogues. Phenoxybenzamine’s pharmacology — α-receptor blockade — points in the opposite direction to these established mechanisms. The evidence pack’s own rationale flags this as a weak mechanistic link, and no clinical or literature evidence currently exists to support the connection. This prediction appears to be driven primarily by the TxGNN model’s network-based score rather than by any known or plausible pharmacological pathway.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Phenoxybenzamine has no active ARTG entries — it is not currently marketed in Australia (0 licences on record).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. Note that this evidence pack flags two related data gaps: TFDA/local product-information warnings and contraindications (blocking severity), and detailed mechanism-of-action data (high severity) — both would need to be sourced before any safety assessment could proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by the TxGNN model score (L5, no trials, no literature), and the proposed mechanism (α-adrenergic blockade) is pharmacologically inconsistent with established glaucoma treatment approaches. There is no basis to advance this candidate at this time.
To proceed, the following is needed:
- Confirmed mechanism-of-action data for Phenoxybenzamine (currently a data gap)
- TFDA/TGA product information warnings and contraindications (currently a blocking data gap)
- Preclinical or mechanistic evidence specifically linking α-adrenergic antagonism to intraocular pressure reduction, given the current rationale points the opposite direction
- Note: within this same evidence pack, the rank-3 candidate (“respiratory failure”, TxGNN score 98.80%, evidence level L4) has 18 literature results with a more plausible mechanistic rationale (catecholamine excess states) and may warrant separate evaluation ahead of this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.